You are here

New Vaccine Candidate for Deadly H7N9 Flu Virus

Thirty-one deaths reported in China (May 8)

A new virus-like particle (VLP) vaccine candidate has been produced for the avian influenza A (H7N9) virus that is responsible for the current deadly flu outbreak in China.

In order to produce an influenza vaccine, the manufacturer — Medicago Inc., based in North Carolina and Canada — requires only the genetic sequence of the viral strain, thus limiting the delays that can occur using traditional manufacturing systems. Manufacturers of current egg-based flu vaccines can take up to 6 months to produce a vaccine for any new strain.

The new H7N9 VLP vaccine is currently being purified in preparation for immunogenicity studies in animal models.

To date, a total of 130 laboratory-confirmed cases of human infection with the H7N9 virus strain, including 31 deaths, have been reported to the World Health Organization (WHO).

Source: Medicago Inc.; May 8, 2013.

More Headlines

First and Only Treatment Reduces Depressive Symptoms Within Days
Bone Marrow Cleared of Leukemia in Almost 60% of Patients
Combination of Two Drugs Could Reduce Tumor Growth
Atezolizumab in Combination with Chemotherapy is the Only First-line Cancer Immunotherapy for ES-SCLC
Pre-clinical Trials Showed Drug Inhibits Fibroblast Activity and Collagen Deposition
PARG Inhibitor Exploits Weakness, Kills Cells
Inexpensive, Wearable Therapy Increases Arm Mobility, Reduces Stiffness
National Statistics Report Factors In Race, Ethnicity for the First Time